Result of AGM

RNS Number : 4274D

Epistem Holdings plc

02 December 2009

 



Epistem Holdings Plc

2 December 2009

Epistem Plc (LSE: EHP), the rapidly growing UK biotechnology company with adult epithelial stem cell expertise in oncology, gastrointestinal and dermatological diseases, announces today that all resolutions at the Annual General Meeting held on 25 November 2009 were passed. 

The Company's amended Articles and Associations can be viewed on the Epistem website at http://www.epistem.co.uk/constitutional-documents.asp.

Epistem Plc
Matthew Walls CEO	[phone]
John Rylands CFO	[phone]
Piper Jaffray Ltd.
Neil Mackison	[phone]
De Facto Communications
Mike Wort / Anna Dunphy	[phone]

Notes to Editors: 

About Epistem 

Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation. 

 

END

 

 

RAGFSFFWFSUSELE